Skip to content

A clinical study on the treatment of acne with the combination of Geshu acupoint bloodletting and Qingcuo granules

A clinical study on the treatment of acne with the combination of Geshu acupoint bloodletting and Qingcuo granules

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025000825
Enrollment
Unknown
Registered
2025-04-22
Start date
2024-01-01
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acne

Interventions

Medicine Group:Oral Qingcuo Granules
Bleeding group:Geshu bleeding
Acupuncture and medicine group:Geshu bleeding and oral Qingcuo granules

Sponsors

Xiangshan Traditional Chinese Medicine HospitalHuangpu DistrictShanghai
Lead Sponsor

Eligibility

Sex/Gender
All
Age
13 Years to 35 Years

Inclusion criteria

Inclusion criteria: 1: Meets the diagnostic criteria for acne 2: Age 13-35 years old gender unlimited 3: Informed consent and willingness to accept research protocol treatment 4: have not taken any oral medication for treating acne within the past month before treatment and have not used any topical medication for treating acne within the past week

Exclusion criteria

Exclusion criteria: 1: Individuals whose age does not meet the inclusion criteria or those with acne caused by contact or medication use 2: Patients with basic diseases such as cardio cerebrovascular diseases diabetes liver and kidney dysfunction or with serious skin infection coagulation dysfunction and other diseases 3: Pregnant or lactating women 4: Incomplete collection of patient data affecting efficacy evaluators

Design outcomes

Primary

MeasureTime frame
Global Acne Grading System;Sex hormones (testosterone estradiol);

Countries

China

Contacts

Public ContactQian Chen

Xiangshan Traditional Chinese Medicine Hospital

wswzj36@126.com13816320609

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026